SPARC · Health Care · 2026-08-21

Sun Pharma Advanced Research Co Ltd

3.3WatchWeak -0.2Stage 2 · wk 14In scan: Pullback Hunter · Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹196.7
-1.44% today
₹6,384 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
4.6
Forward 4.0
ROE
+276.9%
Profit margin +3967.3%
vs 52W High
-29.1%
₹108.7 lo₹277.6 hi
29.1% below 52W high — far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 14
1w13w26w
Week 14 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
19.7%
200 DMA: ₹164.4 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.12x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -7.7% vs MA50 +0.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #26 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #21 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 24w
S4 36w
S4 19w
S2 14w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 9w → S2 11w → S3 3w → S2 24w → S3 5w → S4 8w → S1 5w → S4 36w → S1 12w → S4 19w → S1 6w → S4 12w → S1 3w → S2 14w current
Total tracked: 168 weeks across 15 stage runs.
1M
-8.3%
3M
-6.2%
6M
+47.1%
YTD
+47.2%
1Y
+38.3%
Scan Membership
Pullback Hunter
Latest: 2026-07-21
Prop Scan
Latest: 2026-07-21
Breakout Watch
Latest: 2026-05-18
56 appearances in last 60 days. First seen: 2026-05-18.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 14 · Vol —x
2026-08-20S2
Wk 14 · Vol —x
2026-08-19S2
Wk 14 · Vol —x
2026-08-18S2
Wk 13 · Vol —x
2026-08-17S2
Wk 13 · Vol —x
2026-08-14S2
Wk 13 · Vol —x
2026-08-13S2
Wk 13 · Vol —x
2026-08-12S2
Wk 13 · Vol —x
2026-08-11S2
Wk 12 · Vol —x
2026-08-10S2
Wk 12 · Vol —x
2026-08-07S2
Wk 12 · Vol —x
2026-08-06S2
Wk 12 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹226.2
200 DMA
₹164.4
52W High
₹277.6
52W Low
₹108.7
5D Low
₹192.9
Resistance levels (recent highs)
20d High
₹218.4
60d High
₹277.6
120d High
₹277.6
250d High
₹277.6
Next resistance
+11.0%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.